VivoSeq
Oncology

Metastatic Hepatocellular Carcinoma

5

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Metastatic Hepatocellular Carcinoma is an early-stage landscape with 5 programs across 4 companies. The most active players are BeOne Medicines, BeiGene, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BeOne Medicines

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Eisai logo

Eisai

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Monoclonal antibody

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSSmall molecule240%

Monoclonal antibody leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
Recruiting·BBeOne Medicines·Phase 1·NCT06427941·392 enrolled
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in Combination With Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Participants With Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) After Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound (GDFATHER HCC-01)
Recruiting·CCatalYm GmbH·Phase 2·NCT07219459·104 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)